[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340456-105":59,"doc-detail-340456-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","barriers-and-facilitators-to-next-generation-sequencing-use-in-united-states-oncology-settings-a-systematic-review","Barriers and facilitators to next-generation sequencing use in United States oncology settings - a systematic review","","Next-generation sequencing (NGS) of solid tumors can support treatment decisions, yet its adoption in oncology remains limited. This systematic review searched Embase and MEDLINE (March 2023) for 2012–2023 studies evaluating barriers to and facilitators of NGS uptake in US settings. Twenty-one studies were included, assessing quality with established critical appraisal tools. Complex reimbursement and uncertainty about clinical utility were key barriers; guideline recommendations helped, though insurance often restricted access.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/barriers-and-facilitators-to-next-generation-sequencing-use-in-united-states-oncology-settings-a-systematic-review/340456/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/barriers-and-facilitators-to-next-generation-sequencing-use-in-united-states-oncology-settings-a-systematic-review/340456.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the review address regarding next-generation sequencing (NGS)?","Question",{"text":112,"@type":113},"NGS of solid tumors can inform treatment decisions, but uptake in US oncology settings remains low. The review focuses on identifying barriers and facilitators driving adoption.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were eligible studies selected and appraised?",{"text":117,"@type":113},"Embase and MEDLINE were searched in March 2023 for articles from 2012 to 2023 on barriers and facilitators of NGS adoption for solid tumors. Included studies used surveys, interviews, or observational designs, and quality was assessed with established critical appraisal tools.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main barriers and facilitators found?",{"text":121,"@type":113},"Key barriers included complex reimbursement processes and uncertainties about clinical utility. Recommendations for NGS in clinical practice guidelines were a facilitator, although insurance policies were often more restrictive than guidelines.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340456,1790633364,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","FUTURE ONCOLOGY  \n2024, VOL. 20, NO. 35, 2765–2777  \n[https://doi.org/10.1080/14796694.2024.2390821](https://doi.org/10.1080/14796694.2024.2390821)  \nSYSTEMATIC REVIEW     \nBarriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review  \nAndrea Ferreira-Gonzaleza, Gilbert Kob, Nicole Fuscoc, Fiona Stewartc, Kristin Kistler* , c, Sreevalsa  \nAppukkuttanb, Brian Hocumb, Stefan M Allenb and Svetlana Babajanyand  \na Pathology Department, Virginia Commonwealth University, Richmond, VA 23298-0662, USA; b Health Economics and Outcomes Research, Bayer Healthcare US, L.L.C., Whippany, NJ 07981, USA; c Evidence Generation and Value Communications, Cencora, Conshohocken, PA 19427, USA; d US Medical Aﬀairs, Bayer Healthcare US, L. L.C., Whippany, NJ 07981, USA  \nABSTRACT  \nAim: Next-generation sequencing (NGS) of solid tumors can inform treatment decisions; however, uptake remains low. This objective of this systematic review was to identify barriers to and facilitatorsof NGS in US oncology settings.  \nMaterials & methods: Embase and MEDLINE were searched in March 2023 for articles published from 2012 to 2023 on barriers and facilitators of NGS adoption for solid tumors. Surveys, interviewsand observational studies were eligible. Studies on genetic testing for hereditary cancers and nonUS studies were excluded. The Motheral scale, Joanna Briggs Institute critical appraisal checklist and McGill Mixed Methods Appraisal Tool were used to assess study quality. Data were synthesized narratively.  \nResults: Twenty-one studies were included. Study participants were clinicians, payers and administrators. Key barriers included complex reimbursement processes and uncertainties around clinical utility. Including recommendations for NGS in clinical practice guidelines was a key facilitator, although insurance policies were often more restrictive than guideline recommendations. Conclusion: Uptake of NGS is increasing but barriers remain. Changes to the current reimbursement frameworks are needed to increase access to NGS. The impact of implementing the 2018 National Coverage Determination, which allows access to NGS for all Medicare beneficiaries with advanced cancer, is not yet evident in the published literature.  \nARTICLE HISTORY  \nReceived 21 November 2023 Accepted 7 August 2024  \nKEYWORDS  \nclinical oncology; genetic testing; high-throughput sequencing; massive parallel sequencing; next-generation sequencing; precision medicine; qualitative evidence synthesis; systematic review  \n1. Introduction  \nNext-generation sequencing (NGS) – also known as massive parallel sequencing – is a high throughput analysis method that enables the rapid processing of billions of DNA strands in a single sample. In the oncology context, NGS can be used to identify actionable mutations in the genes of a tumor that are likely to benefit from early treatment, such as EGFR, ALK, ROS1 and NTRK in non-small cell lung cancer (NSCLC) [1] . It has high specificity, moderate to high sensitivity and the ability to simultaneously detect multiple types of variants, including fusions, mutations and amplifications. Known biomarkers detected using NGS can indicate poor or favorable prognosis, predict resistance to therapies and inform treatment decisions [2] . Furthermore, NGS has been shown to be cost-saving compared with single gene testing strategies in some tumor types [3,4] . Targeted  \ntherapies have been developed in recent years to treat tumors with a wide range of predictive biomarkers, including EGFR, BRAF V600, MET, ALK, ROS1 and RET [5] . Along with cancer-specific treatments, several tumoragnostic therapies are now available that target specific genetic changes, regardless of where the cancer originated in the body. These include dabrafenib plus trametinib for solid tumors with BRAF V600E mutation [6] and larotrectinib and entrectinib for NTRK fusions in solid tumors [7,8] .  \nTargeted therapy options have led to impro","cbCailvhXTC6T1Yf","https://ap.wps.com/l/cbCailvhXTC6T1Yf","pdf",1316301,13,"English","# Introduction\n# Materials & methods\n# Results\n## Barriers\n## Facilitators\n# Conclusion","[{\"question\":\"What problem does the review address regarding next-generation sequencing (NGS)?\",\"answer\":\"NGS of solid tumors can inform treatment decisions, but uptake in US oncology settings remains low. The review focuses on identifying barriers and facilitators driving adoption.\"},{\"question\":\"How were eligible studies selected and appraised?\",\"answer\":\"Embase and MEDLINE were searched in March 2023 for articles from 2012 to 2023 on barriers and facilitators of NGS adoption for solid tumors. Included studies used surveys, interviews, or observational designs, and quality was assessed with established critical appraisal tools.\"},{\"question\":\"What were the main barriers and facilitators found?\",\"answer\":\"Key barriers included complex reimbursement processes and uncertainties about clinical utility. Recommendations for NGS in clinical practice guidelines were a facilitator, although insurance policies were often more restrictive than guidelines.\"}]","Barriers and facilitators to next-generation sequencing use in United States oncology settings - a systematic review | PDF",1790036660,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90a2a8be93533485ebdf3cfc0e78158e.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0eaa75ba831ab67167a3c58595b7b562.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/229a590c345a26ca9229ddb7695281a4.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c575dbad0dba5496ab8e5c9ebd02834b.webp",980,1268]